J & J raises annual profit forecast on strong demand for top-selling anti-inflammatory drug

Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its top-selling drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit. The company's shares were up about 2% in premarket trading. Investors are focused on how Johnson…#johnsonjohnson #stelara

Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news